Minaris offers GMP manufacturing services for viral vectors across all stages of development, from early-phase clinical trials to commercial supply. Our global network of facilities supports the production of AAV, lentivirus, retrovirus and other vector types using suspension or adherent platforms.
Whether you’re advancing a gene therapy, cell therapy or vaccine, we provide the infrastructure, flexibility and regulatory alignment to meet your needs.
With end-to-end GMP infrastructure and multi-suite facilities, Minaris delivers both clinical-scale and commercial-scale viral vector manufacturing. Capabilities include:
Multiple production suites are designed for the segregation of different vector types and biosafety levels
Single-use bioreactor platforms capable of scaling up to 2,000L
Suspension and adherent culture for AAV and LVV, with AAV triple plasmid transfection and TESSA® technology, plus LVV transfection, XOFLXTM packaging and stable producer cell lines
Downstream purification via clarification, chromatography, ultrafiltration/diafiltration (UF/DF), as well as other platform processes
Phase-appropriate GMP documentation and global regulatory submission support (IND, IMPD, BLA/MAA)
GMP manufacturing is fully integrated with in-house testing services, reducing timelines, minimizing logistics-related risks and ensuring analytical continuity throughout your program lifecycle.
QC and analytical support include:
Lot release testing
Biosafety testing
Viral clearance studies
Stability and potency testing
Assay qualification and validation
Minaris’ viral vector GMP manufacturing is conducted at our Philadelphia facility. At the same time, our broader global network of state-of-the-art sites in North America, Europe and Asia provides cell therapy manufacturing, testing and technology transfer. Together, these harmonized operations ensure worldwide support and consistent quality for our partners.
Key site features include:
intro-section does not exist
Minaris Advanced Therapies is dedicated to helping innovators in cell and gene therapy succeed. Whether you are in early-stage development or preparing for commercial launch, our end-to-end expertise, global reach and commitment to quality make us the ideal partner for cell and gene therapy manufacturing and GMP biosafety and analytical testing of all biologics.
